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Abstract
Background: The small molecule Halofuginone (HF) is a potent regulator of extracellular matrix (ECM ) gene
expression and is unique in its therapeutic potential. While the basis for HF effects is unknown, inhibition of TGFb
signaling and activation of the amino acid restriction response (AAR) have been linked to HF transcriptional control
of a number of ECM components and amelioration of fibrosis and alleviation of autoimmune disease by regulation
of Th17 cell differentiation, respectively. The aim of this study was to generate a global expression profile of HF
targets in epithelial cells to identify potential mediators of HF function in this cell type.
Results: We report that HF modulation of the expression of the ECM remodeling protein Mmp13 in epithelial cells
is separable from previously reported effects of HF on TGFb signal inhibition, and use microarray expression
analysis to correlate this with transcriptional responses characteristic of the Integrated Stress Response (ISR).
Conclusions: Our findings suggest activation of the ISR may be a common mechanism underlying HF biological
effects.
Background
Natural product small molecules and their derivatives
have had a profound impact on the development of
treatments for a variety of human diseases. Understand-
ing the molecular pathways mediating the biological
effects of clinically useful small molecules facilitates the
development better-tailored therapeutics. In recent
years, considerable interest sparked around Halofugi-
none (HF) rel-7-bromo-6-chloro-3-[3-[(2R,3S)-3-
hydroxy-2-piperidinyl]-2-oxopropyl]- 4(3H)-Quinazoli-
none, a racemic derivative of the anti-malarial plant qui-
nazoline febrifugine {[3-[(2R,3S)-3-hydroxy-2-
piperidinyl]-2-oxopropyl]-4(3H) quinazolinone} (Figure
1). Initially used as a broad-spectrum anti- protozoal,
interest in the clinical potential of HF was spurred by
the discovery that HF can ameliorate pathological extra-
cellular matrix (ECM) deposition and remodeling [1,2].
These and numerous subsequent studies have estab-
lished that HF is a potent anti-fibrotic, anti-angiogenic,
anti-metastatic and ECM modulator in vivo,a n da n
inhibitor of ECM gene expression, epithelial to
mesenchymal (EMT) and fibroblast to myofibroblasts
t r a n s i t i o ni nv i t r o[ 3 - 9 ] .A sar e s u l t ,H Fi si nc l i n i c a l
trials for the treatment of scleroderma and as an anti-
angiogenic for the treatment of Kaposi’s sarcoma and
solid tumors [10-13].
HF inhibition of Transforming Growth Factor-b
(TGFb) signaling has been proposed as a major mechan-
ism for HF biological activity [8,14,15]. Treatment of
cultured cells with HF has been linked to decreased
levels of Phospho-Smad3, and specifically in epithelial
cells, this has been proposed to result from HF-
mediated transcriptional up-regulation of Smad7, a
negative regulator of the pathway [14]. However, HF
concentrations required to inhibit TGFb signaling in
epithelial cells are substantially higher (>100 nM) than
concentrations shown to have biological consequences
at the level of gene expression (1-10 nM) or HF plasma
levels in animal models where HF exhibited biological
activity (4 nM -10 nM) [2,4,5,14].
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lab, (2009) demonstrates that HF modulates effector T-
cell differentiation by activating the amino acid restric-
tion response (AAR) in vivo and in vitro [16]. Impor-
tantly, AAR stress recapitulates the specificity of this
modulation, indicating that AAR activation explains the
effects of HF on T-cells [16]. This activity of HF
occurred without any detectable change in TGFb signal-
ing in treated T-cells [16]. These data have been used to
suggest that regulation of TGFb signaling is not neces-
sary for the biological effects of HF in T-cells. This
raises the question if such a mechanism may also be
employed in other cell types that may be targets for HF
action, such as fibroblasts and epithelia. Because ECM
remodeling, and epithelial-mesenchymal transition, may
link changes in epithelial cell phenotype to fibrosis, we
have investigated early responses to HF in this cell type
[17-21].
NMuMG mammary epithelial cells have previously
been shown to respond to HF at the level of Smad7
expression and Phospho-Smad3 down-regulation, albeit
at the high dose of 100 nM HF [14]. In an effort to deter-
mine the early effectors mediating HF activity, we under-
took an unbiased approach to examine early, sensitive
responses to HF in this cell type. We show that treatment
of cultured epithelial cells with HF results in upregulation
of Mmp13, a reported HF target and that this response is
clearly separable from Smad7 activation and inhibition of
TGFb signaling [22]. Using this assay as a backdrop, we
p e r f o r m e dg e n o m ew i d em i c r o a r r a ya n a l y s i sa n dr e p o r t
the expression profile of HF treated cells. We find that
HF treatment induces the transcription of many genes
characteristic of an ATF4-mediated Integrated Stress
Response (ISR) [16,23,24]. The HF transcriptional targets
from this study provide a quantitative biological readout
of the early downstream effects of HF, and suggest that
HF activity in epithelial cells results in transcriptional
activity characteristic of an ISR stress. Importantly, while
the ISR can be triggered by several defined stressors, the
upregulation of known AAR-specific markers, and
absence of ER stress targets in our data, suggest that HF
does not generally activate ER stress responses and is
more consistent with a function for HF in the specific
activation of the AAR that is shared between epithelial
cells and T-cells [16,23,24]. Thus, our results point to
AAR activation as a more general component of the bio-
logical response to HF.
Results
Modification of Halofuginone into transcriptionally active
and inactive functional analogs
To develop a specific negative control for HF, we
undertook to modify HF into a non-functional analog
that was structurally similar to the parent compound,
but did not elicit effects on the early transcriptional tar-
get Smad7. Previous reports studying the structure
activity relationship (SAR) of the anti-malarial activity
of HF and febrifugine analogs provided valuable insights
for the design of active and inactive analogs as control
compounds [25-28]. In general, modifications to the
quinazolone-system were tolerated, while blocking the
basic piperidine nitrogen did result in inactivation of
the antimalarial activity (Ralph Mazitschek, unpublished
results). In an effort to synthesize analogs that would be
suitable for the development of an affinity purification
matrix for the molecular targets of HF, we have identi-
fied MAZ1319 as suitable ligand (Figure 2). In
MAZ1319, (6-chloro-3-(3-((2S/R, 3R/S)-3-hydroxypiperi-
din-2-yl)-2-oxopropyl)-7-((trimethylsilyl)ethynyl)quinazo-
lin-4(3H)-on the Br on the quinazoline is substituted
with a bulky trimethyl silyl (TMS) group. In contrast
the acylation of the piperidine nitrogen as tert-butyl car-
bamante, MAZ1310 ((2S/R,3R/S)-tert-butyl 2-(3-(7-
bromo-6-chloro-4-oxoquinazolin-3(4H)-yl)-2-oxopro-
pyl)-3-hydroxypiperidine-1-carboxylate), was not toler-
ated (Figure 2).
The relative activation of Smad7 transcription by HF,
MAZ1310 and MAZ1319 was determined in NMuMG
cells, in which HF was previously reported to induce
Smad7 expression (Figure 2) [14]. To test analog activ-
ity, NMuMG cells were treated for 8 hours with increas-
ing concentrations of HF, MAZ1310 or MAZ1319
ranging from 0.010 μMt o1μM, and Smad7 expression
levels were analyzed by quantitative RT-PCR. A mini-
mum of 0.03 μM HF was required to induce Smad7
transcription in this assay, while 0.10 μM MAZ1319
induced the expression of Smad7. In contrast, MAZ1310
did not activate Smad7 transcription at any concentra-
tion tested. Thus, the addition of a bulky substituent on
the quinazoline, while reducing HF potency, did permit
downstream transcriptional regulation. In contrast,
blocking of the secondary amine on the piperidine ring
in MAZ1310 caused a complete loss of HF transcrip-
tional activity.
Figure 1 Halofuginone (HF).
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Page 2 of 11HF induces Mmp13 transcription without affecting TGFb
signaling
To assay the biological activity of the HF analogs more
broadly, we determined the effects of HF derivatives on
Mmp13 expression. Mmp13 was previously reported to
be up-regulated by HF in hepatic stellate cells [22]. Con-
sistent with the relative effects of the HF analogs on
Smad7 expression, MAZ1319, but not MAZ1310
Figure 2 HF can be modified into functional and non-functional analogs. (A) Structures of MAZ1319 and (B) MAZ1310. (C) HF and
MAZ1319 but not MAZ1310 induce transcription of Smad7 (C) in NMuMG cells after 8 hours of treatment. All samples were normalized to b-
Actin transcript levels. The fold induction of Smad7 is calculated relative to DMSO vehicle treatment)
Kamberov et al. BMC Research Notes 2011, 4:381
http://www.biomedcentral.com/1756-0500/4/381
Page 3 of 11activated Mmp13 transcription (Figure 3). However,
Mmp13 expression was induced by as little as 0.01 μM
HF, a three fold lower concentration than the minimum
required to induce Smad7 transcription. MAZ1319 also
exhibited approximately 3 fold higher potency in activat-
ing Mmp13 transcription relative to Smad7 activation.
These results are intriguing in light of the critical role
that has been proposed for Smad7 in HF biological
activity [14].
Since Smad7 is an inhibitor of TGFb signaling, we
tested whether or not 0.01 μM HF treatment results in
TGFb inhibition and found no detectable decrease in
activated Smad3 under these (Figure 3). Reduction of
phosphorylated Smad3 levels required treatment with a
substantially higher dose of HF (0.1 μM), consistent
with previously published reports [14]. Since Mmp13
induction occurs at a dose of HF at which neither
induction of the TGFb inhibitor Smad7 nor a decrease
in the level of TGFb signaling in these cells can be
observed, it seems unlikely that Mmp13 induction is
mediated through effects on TGFb signaling. To explore
the molecular basis for the observed transcriptional
activity, we generated a global expression profile for HF
under conditions where Mmp13 but not Smad 7 expres-
sion is altered by HF.
Gene expression profiling reveals HF activates expression
of Integrated Stress Response effectors
A broad spectrum HF expression profile was generated
by microarray transcriptional analysis. NMuMG cells
were treated with 0.01 μMH Fo r0 . 0 1μM MAZ1310
for 8 hr. Each treatment was done in triplicate. Cells
were then harvested and total RNA was extracted. RNA
samples were processed for microarray analysis using
the Mouse One Array gene chip. All arrays were per-
formed in triplicate. Microarray data is available via the
Gene Expression Omnibus, record number GSE30667.
As expected, Mmp13 expression was up-regulated, but
not Smad7.
HF treatment altered the expression of multiple
genes, involved in a variety of biological processes
including signal transduction, transcriptional regula-
tion, redox and cell metabolic homeostasis demonstrat-
ing that HF exerts widespread transcriptional effects
(Figure 4). Strikingly, HF potently induced the expres-
sion of signature Atf4/Integrated Stress Response effec-
tor genes including Atf5, Ddit3, Trib3, Ndrg1,
Gadd45a and Slc1a4 (Figure 5) [16,23,24]. To a lesser
extent, HF also induced the expression of the tran-
scription factors Atf3 and Atf4 itself (Figure 5). When
Atf4/ISR genes were tested against gene expression in
HF and MAZ1310 (gene set: Atf4/ISR genes, pheno-
type: HF treatment), GSEA indicated a high statistical
significance (Enrichment Score = 0.962, p = 0.000,
Normalized Enrichment Score (NES) = 1.27 and FDR
q-value = 0.000; Figure 5). All 19 Atf4/ISR genes were
t h ec o r em e m b e r so ft h eleading-edge subset in GSEA
term, meaning all genes were highly correlated with
HF intervention (Table 1) and appeared before the
point where the running sum reached its maximum
deviation from zero (Figure 5). The up-regulation of
these transcripts is characteristic of a coordinated cel-
lular response to a set of defined stressful conditions,
as mediated by the transcription factor Atf4
[16,22,23,29]. To provide an additional, independent
validation of the microarray results, quantitative RT-
PCR (qRT-PCR) was used to determine the relative
expression of Atf5, Trib3, Ddit 3, Ndrg1, Gadd45a,
and Scl1a4, Atf3, Atf4, Ero1l and Yars and consistent
with the microarray results, HF, but not MAZ1310,
consistently up-regulated the expression of these ISR
genes (Figure 5). Activation of the Atf4/ISR in the
absence of detectable TGFb signaling inhibition in HF
treated epithelial cells points to additional signaling
mechanisms that may be responsible for HF effects in
vivo.
Discussion
Derivitization of Halofuginone implicates structural
features required for transcriptional regulation
We have derivatized HF into functional and non-func-
tional derivatives. MAZ1310, in which the secondary
amine is blocked as carbamate, failed to induce tran-
scriptional responses by all HF targets tested. Our data
indicate that the piperidine ring is critical for HF activ-
ity, which is consistent with observations that modifica-
tions of the basic secondary nitrogen abolishes HF and
febrifugine anti-malarial activity [25-28]. The basis for
loss of activity in HF derivative MAZ1310 may be an
inability to bind HF targets or may be due to the forma-
tion of a non-functional complex between this analog
and HF binding targets. Consistent with this idea, we
have found that HF, but not MAZ1310, is able to com-
pete a recently identified HF binding protein in an in
vitro affinity purification assay [30].
Conservation of functional moieties was also observed
for the quinazoline ring. Addition to the quinazoline
ring in MAZ1319 did not inhibit transcriptional regula-
tion activity. However, we found that while functional,
MAZ1319 was slightly less potent than its parent com-
pound. Thus while, this compound is likely to interact
with direct HF mediators, it may do so with decreased
affinity, leading to reduced potency. The ability of
MAZ1319 to recapitulate HF transcriptional regulation
has potential implications for the development of an HF
affinity reagent, which can be used for the identification
of HF interacting proteins. Collectively, our work with
HF derivatives suggests that the two reported functions
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Page 4 of 11Figure 3 HF induces Mmp13 expression in assay that does not inhibit TGFb signaling or induce Smad 7. (A) HF and MAZ1319 but not
MAZ1310 induce transcription of Mmp13 (A) in NMuMG cells after 8 hours of treatment, consistent with activities determined for HF analogs for
Smad7 induction. Note that 0.01 μM HF treatment induces Mmp13 expression, but not Smad7 expression in this assay. All samples were
normalized to b-Actin transcript levels. The fold induction of Mmp13 is calculated relative to DMSO vehicle treatment. (B) HF does not affect
endogenous Phospho-Smad3 levels in cells at minimum concentration required to induce Mmp13 expression (0.01 μM). Cells were treated with
the indicated HF concentrations or with DMSO (-) and were cultured in complete media for 8 hours. Cells were harvested after 8 hours and
processed for SDS-PAGE analysis. Phospho-Smad3 was detected using a polyclonal Phospho-Smad3 antibody and Tubulin levels are shown as a
loading control.
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Page 5 of 11of HF, as an anti-protozoal and as a transcriptional reg-
ulator require similarly structured binding pockets in
effector proteins.
The Atf4/Integrated Stress Response is a putative
mediator of HF biological activity
HF therapeutic effects have been linked to HF-mediated
inhibition of TGFb signaling, in part through upregula-
tion of Smad7 [7,14,15]. In contrast, the work of Sun-
drud and colleagues has implicated the AAR, which is
one of several pathways that may specifically trigger the
Atf4/ISR downstream of HF modulation of T-cell differ-
entiation [16]. These observations do not explain prior
work on HF in epithelial cells where HF has been
shown to alter ECM gene expression and ameliorate
fibrosis. In an effort to explore the basis for HF effects
on epithelial cells, we generated a transcriptional profile
of HF target genes using a physiologically relevant con-
centration of HF. We find that Mmp13 is up-regulated
by HF in epithelial cells and that this activation is clearly
separable from Smad7 activation/TGFb inhibition.
Moreover, we find that under these conditions, HF
alters the expression of a broad spectrum of transcripts,
and specifically up-regulates the expression of a group
of genes induced by the ISR, as a consequence of Atf4
up-regulation.
The ISR is a coping mechanism that allows cells
experiencing metabolic, oxidative, hypoxic, or ER stress
to conserve resources while adjusting gene expression to
alleviate the effects of stress conditions [23,31-33]. The
core ISR program of transcriptional and translational
control is activated by all of these stimuli, and includes
phosphorylation and consequent inactivation of eIF2a
and upregulation of Atf4 translation and transcription
leading to a program of decreased protein translation
and metabolic expenditure [23,31-33]. HF treatment of
NMuMG epithelial cells let to the induction of Atf4
itself, as well as that of the bZIP transcription factors
Atf3, Atf5 and Ddit 3. These proteins dimerize with
each other and with other C/EBP family transcriptions
factors and regulate the expression of other ISR effectors
[29]. While Atf3 and Atf5 have contextually regulated
roles as pro-survival and pro-apoptotic mediators of the
ISR, Ddit3 appears to be exclusively pro-apoptotic
[32,34-36]. Trib3, which was also induced by HF, is a
negative feedback regulator of the Atf4-ISR, and is a
transcriptional target of Ddit3 [36,37]. Gadd45a is
induced by Atf4, and is a cell cycle checkpoint regulator
required for proper S-phase control and for mainte-
nance of genome stability under stressful conditions
[38-40]. Consistent with a response to remediate stress,
HF treatment resulted in the increased expression of
multiple genes involved in amino acid import and synth-
esis. Specifically, elevated transcription of the amino acid
transporters Slc1a4 and Slc7a11, tRNA synthetases, and
asparagine synthetase (Asns) was apparent [23,24]. It is
interesting to note that Asns, Atf3, Trib3 and Slc7a11
all contain amino acid response elements. Previously
published expression profiles of cells undergoing nutri-
e n td e p r i v a t i o n ,a l s os h o wt h es a m es u b s e to fg e n e s
Figure 4 Global expression profiling implicates multiple biological pathways downstream of HF. (A) Relative abundance of HF
transcriptional targets based on biological ontogeny. Biological processes which accounted for one percent or more and p < 0.001 are
specifically shown. Note that stress response and unfolded protein response characteristic genes are among those showing enrichment.
Enrichment analysis was performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. (B) Validation plot
showing high correlation between array results and validation by quantitative RT-PCR. Fold-change values of 21 genes from the microarray (y-
axis) are plotted against the corresponding values from the qRT-PCR (x-axis). Each value is the log2-ratio of the treated vs. the untreated samples.
The slope of the regression line is 0.704 and the Pearson correlation coefficient is 0.938 (p-value 1.33e-11), indicating highly significant
agreement.
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Page 6 of 11Figure 5 HF upregulates the expression of Integrated Stress Response effector genes. (A) A heat-map of signature genes related to the
Integrated Stress Response (ISR) is displayed. Among reported genes in previous studies, nineteen genes were chosen if absolute fold-change
was greater than 2 and q-value was less than 0.001. Measurement values were normalized to have mean zero and variance one per gene. The
heat-map was generated using matrix2png. (B) Validation of HF induction of selected ISR genes by quantitative RT-PCR (qRT-PCR). qRT-PCR was
preformed on an independent set of samples from an 8 hour 0.01 μM HF or MAZ1310 treatment. qRT-PCR data is expressed as the mean fold
change in the level of the indicated transcript between HF and MAZ1310 treated samples, and the standard error of the means (SEM) is
included. Each condition was assayed in triplicate, and the experiment was repeated three times. Aggregate results are shown. (C) GSEA plot.
Enrichment Score (ES) was 0.962 and its nominal P-value < 10
-3. top: Enrichment profile where running ES for the Atf4/ISR gene set as the
analysis walks along the ranked list; middle: The Hits shows where the members of the Atf4/ISR gene set appear in the ranked list; bottom:
Ranked list metric measures a gene’s correlation with a phenotype (i.e. Halofuginone treatment).
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Page 7 of 11being up-regulated, suggesting that HF treatment may
mimic this stimulus [16,24,31]. In contrast, a character-
istic response to ER stress is the increased transcription
of ER chaperones such as GRP78/BiP, which was not
detected in our expression analysis [16,33,41]. This is at
least in part because the ER stress pathway activates
XBP1 and ATF6 as well as the eIF2a/ATF4 cascade
[16,33]. In contrast, the AAR, which is activated by
unloaded tRNAs is characterized by the upregulation of
amino acid transporters and genes containing amino
acid response elements as seen in our array [16,24].
Work by Sundrud and colleagues showed that the
effects of HF on T-cells could be completely reproduced
by amino acid depletion and amino acid supplementa-
tion completely reversed the effects of HF in T-cells
[16]. In light of these data and the similarity in upregu-
lated genes previously reported to be induced by nutri-
ent deprivation, it seems plausible that the AAR is at
least in part responsible for HF effects in epithelial cells,
but not necessarily restricted to this. In agreement with
this idea, recent work in our laboratory has revealed
that treatment with HF induces the phosphorylation of
eIF2a in NMuMG cells consistent with observations on
HF activation of the AAR in T cells [Malcolm Whitman
unpublished data, 16]. Together, these data suggest that
activation of the Atf4-ISR may be a common feature of
HF treated cells in vivo and in vitro. Moreover, as in T-
cells, this HF activity is clearly distinct from HF-
mediated suppression of TGFb signaling.
Since HF has been implicated in the suppression of
tumor growth, metastasis, and inhibition of EMT, it is
interesting to speculate on the potential role of ISR acti-
vation in mediating these effects. However, to date,
these HF biological activities have largely been attribu-
ted to HF-mediated inhibition of TGFb signaling
[7,14,15]. The ability of HF to activate the ISR in multi-
ple cell types without affecting TGFb signaling levels
presents the possibility that the Atf4/ISR should be
examined as a separable mediator of HF biological
effects. Our data correlate HF activation of the Atf4/ISR
with changes in the transcription of multiple genes,
including ECM regulators such as Mmp13 which was
previously linked to HF anti-fibrotic effects on fibrotic
potential in a liver cirrhosis model [22]. Whether this is
a correlative or causal effect is the basis of current
experiments in our laboratory. It has already been
reported that HF activation of the Atf4/ISR via AAR sti-
mulation is sufficient to explain HF biological effects in
T-cells, and in turn HF-dependent amelioration of auto-
immune disease [16]. At present, the mechanism by
which Atf4/ISR activation and or the AAR specifically
could modulate fibrotic disease is not known. It is inter-
esting, however, that the Atf4/ISR was recently impli-
cated as a common mechanism employed by a number
of promising chemotherapeutic drugs. For example,
induction of the ISR is critical for the ability of the pro-
teosome inhibitor class of anti-tumor compounds to
inhibit cell proliferation and sensitize cells to apoptosis
Table 1 GSEA results of Atf4/ISR target genes
PROBE RANK IN GENE LIST RANK METRIC SCORE RUNNING ES CORE ENRICHMENT
1 Ddit3 1 0.860 0.098 Yes
2 Atf5 2 0.756 0.183 Yes
3 Ndrg1 3 0.744 0.268 Yes
4 Trib3 5 0.731 0.350 Yes
5 Car6 8 0.678 0.427 Yes
6 Gadd45a 9 0.636 0.499 Yes
7 Pmaip1 13 0.562 0.563 Yes
8 Ereg 18 0.498 0.619 Yes
9 Slc1a4 20 0.491 0.675 Yes
10 Txnip 26 0.449 0.725 Yes
11 Atf3 80 0.349 0.762 Yes
12 Ero1l 124 0.317 0.795 Yes
13 Slc7a11 155 0.293 0.827 Yes
14 Wars 156 0.292 0.860 Yes
15 Clcn3 176 0.282 0.891 Yes
16 Myc 200 0.268 0.920 Yes
17 Gadd45g 262 0.248 0.944 Yes
18 Asns 593 0.189 0.947 Yes
19 Atf4 673 0.179 0.962 Yes
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Page 8 of 11[32,42]. Importantly, HF effects on autoimmune disease
models are cytoprotective, suggesting that enhancement
of apoptosis or decrease proliferation are not likely to
be the molecular mechanism employed by HF in this
case [16]. Current work in our laboratory is focused on
examining the extent to which activation of the Atf4/
ISR and the AAR specifically can mimic HF biological
effects, and exploring the molecular basis for Atf4/ISR
mediation of HF activity in these contexts.
Conclusions
Our global expression profile of early, low dose HF
responses indicates that activation of the ISR is a potent
response to HF treatment and may be functionally rele-
vant to HF biological effects in a multiple cell types.
Methods
Synthesis of HF analogs
1 kg of 10% pure HF was received as a gift from Hang-
poon Chemical Co. (Seoul, South Korea), which was
further purified via HPLC to >99% purity and used for
experiments.
MAZ1310 (2S/R,3R/S)-tert-butyl2-(3-(7-bromo-6-
chloro-4-oxoquinazolin-3(4H)-yl)-2-oxopropyl)-3-hydro-
xypiperidine-1-carboxylate. 982 mg di-tert-butyldicarbo-
nate in 10 mL DMF were added to a solution of 1.5 g
Halofuginone hydrobromide and 1.3 mL diisopropy-
lethylamine in 100 mL. The reaction mixture was stirred
for 16 h at room temperature. After addition of water
the aqueous layer was extracted three times with diethyl
ether. The combined organic layers were dried over
sodium sulfate and evaporated to dryness. The crude
product was purified on silica gel with dichloromethane/
methanol to yield the desired Boc protected product as
white solid in quantitative yield.
MAZ1319 (6-chloro-3-(3-((2S/R,3R/S)-3-hydroxypiper-
idin-2-yl)-2-oxopropyl)-7-((trimethylsilyl)ethynyl)quina-
zolin-4(3H)-one). 10 mg of (2S/R,3R/S)-tert-butyl 2-(3-
(6-chloro-4-oxo-7-((trimethylsilyl)ethynyl)quinazolin-3
(4H)-yl)-2-oxopropyl)-3-hydroxypiperidine-1-carboxylate
are dissolved in 500 uL dichloromethane, followed by
the addition of 50 uL TFA. The reaction mixture is stir-
r e da tr o o mt e m p e r a t u r ef o r5ha n dt h es o l v e n ti s
removed under reduced pressure. The product is used
without further purification as trifluoroacetate.
NMuMG cell culture and treatment with HF
NMuMG cells were a gift from Dr. Sheila Thomas (Har-
vard Medical School/Beth Israel Deaconess Medical
Center) and were cultured in DMEM supplemented
with 10% FBS, 10 ug/ml Insulin (Sigma Aldrich) and
Pen/Strep. For treatment of NMuMG cells, cells were
freshly plated into complete growth media and 45
minutes later HF or HF analogs diluted in acidified
DMSO was added at the indicated concentrations.
Immunohistochemistry
NMuMG cells were treated with the indicated HF con-
centrations or with DMSO (-) and were cultured in
complete media for 8 hrs prior to harvest. To assess
Phospho-Smad3 levels, cells were lysed in modified
RIPA (50 mM Tris, 150 mM NaCl, 25 mM b-glycero-
phosphate, 100 mM sodium fluoride, 2 mM sodium
orthovanadate, 10 mM sodium pyrophosphate, 20 nM
Calyculin, cOmplete EDTA-free protease inhibitors mix
(Roche Applied Science), 3 mM PMSF, 1 mM EDTA,
1% NP-40, 0.5% sodium deoxycholate, and 1 mM DTT).
Phospho-Smad3 was detected with Phospho-Smad3
(Ser423/425)/Smad1 (Ser463/465) antibody (Cell Signal-
ing).processed by SDS-PAGE analysis. 2 ng/ml TGFb
s t i m u l a t i o no fN M u M G sf o r3 0m i n u t e si nt h i sa s s a y
was used as a positive control to determine size of Phos-
pho-Smad3 on the Western blot. Monoclonal anti-a-
Tubulin Clone DM1A (Sigma Aldrich).
Quantitative RT-PCR
NMuMG cells were harvested 8 hr post treatment with
varying concentrations of HF, vehicle or derivatives
MAZ1319 and MAZ1310 and washed with ice-cold
PBS. Samples for each PCR experiment were in biologi-
cal triplicate. Total RNA was extracted using TRIzol
Reagent (Invitrogen) according to the manufacturer’s
protocol. The extracted RNA was then treated with
RQ1-DNAse I (Promega) for 30 min and subsequently
extracted with Phenol-Chloroform-Isoamyl Alcohol
(Ambion), followed by a Chloroform (Sigma) extraction
and precipitated with Ammonium Acetate/Ethanol.
Total RNA was quantitated and checked for purity on
the NanoDrop1000 spectrophotometer (Thermo Scienti-
fic). 0.5 μg total RNA was used as template per cDNA
reaction. cDNA reactions were carried out according to
standard protocols using oligo-dT (Roche Applied
Science) primer, MMLV-RT (Promega) reverse tran-
scriptase and RNAse Out (Invitrogen). A no RT control
was included for each experiment. Quantitative RT-PCR
(qRT-PCR) was performed on the LightCycler480
(Roche) using Universal Probe Library (Roche) probe-
based PCR method. RT-PCR primers for each target
were designed using to Roche Universal Probe Library
Assay Design Center (https://www.roche-applied-
science.com/sis/rtpcr/upl/acenter.jsp?id=030000) with
sequences and appropriate UPL probes. RT-PCR reac-
tions were performed according the manufacturers pro-
tocol using the Universal Probe Library LightCycler480
Probes Master (Roche) reaction mix. qRT-PCR condi-
tions were as follows: 1 Cycle: 95°C 10 min; 45 Cycles:
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Page 9 of 1195°C 10 sec, 60°C 30 sec, 72°C 1 sec; 1 Cycle: 40°C 30
min. Ct values were calculated using the Roche Light
Cycler 480 Software Release 1.2.0.0625 Analysis Pro-
gram. Each PCR was done in triplicate. All samples
were normalized to Beta Actin and the relative concen-
tration of each sample was calculated using the ddCt
method relative to DMSO or MAZ1310 treated samples
as indicated. Each experiment was repeated at least in
duplicate. The fold change in expression of each target
gene was calculated using the mean relative concentra-
t i o n sf r o me a c he x p e r i m e n ta sc o m p a r e dt oD M S O
vehicle or MAZ1310 treatments alone, as indicated. p
values were calculated using the Student’s T-test.
Microarray analysis
NMuMG cells treated with 10 nM HF or 10 nM
MAZ1310 for 8 hrs in complete media. Each treatment
was done in biological triplicate. Cells were then har-
vested and total RNA was extracted as described pre-
viously. Purified RNA samples were submitted to
Phalanx Biotech for microarray analysis. A detailed
description of Phalanx Biotech company microarray pro-
cedures can be found at http://www.phalanxbiotech.
com/. We used Phalanx Mouse Whole Genome OneAr-
ray to measure mRNA abundance of HF-treated and
MAZ1310 control samples. Each array was performed in
triplicate. A probe was excluded from the data analysis
if it had negative/missing measurement value in any of
eighteen samples. The resulting 21,973 probes were
used to perform quantile-normalization to have the
same distribution of measurement values across the
eighteen samples [43]. Then 21,973 probes were mapped
into the official gene symbols and were aggregated into
17,454 genes by taking median value of the multiple
measurements for each gene. A moderated t-test was
used to detect differentially expressed genes between HF
treated and MAZ1310 control samples [44]. Q-value
was used as a measure of significance to take into
account simultaneous tests of thousands of genes
[45,46]. We conducted Gene Set Enrichment Analysis
(GSEA), a computational method that determines
whether a priori defined set of genes show significantly
significant, concordant differences between two pheno-
type classes [47]. In our case, 19 genes Atf4/ISR genes
constitute as a predefined set and HF status is a pheno-
type with two classes, HF and MAZ1310.
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